共查询到17条相似文献,搜索用时 159 毫秒
1.
目的:评价奥硝唑三联疗法治疗幽门螺杆菌(Hp)相关的消化性溃疡病的疗效及其安全性。方法:将Hp检测阳性,内镜检查为活动期十二指肠溃疡的患者分为治疗组:雷贝拉唑,克拉霉素,奥硝唑;对照组:雷贝拉唑,克拉霉素,替硝唑;连用1周。然后两组继续使用雷贝拉唑1周。第28天复查内镜并检测Hp。结果:疗程结束后第28天内镜检查结果和Hp检测结果两组对比无统计学差异。结论:雷贝拉唑、克拉霉素、奥硝唑三联疗法对Hp相关的消化性溃疡病具有良好的治疗作用和安全性。 相似文献
2.
目的:比较泮托拉唑与奥美拉唑三联疗法治疗十二指肠溃疡的疗效与不良反应;方法:将116名患者随机分为治疗组和对照组各58例,分别采用泮托拉唑与奥美拉唑三联疗法,两组疗程相同,运用对照法观察二种方法治疗十二指肠溃疡的疗效及副作用;结果:泮托拉唑三联疗法治疗十二指肠溃疡总有效率、主要症状消失率与缓解率均较奥美拉唑组为优,其不良反应相当;结论:泮托拉唑三联疗法治疗十二指肠溃疡见效快,依从性好,安全有效。 相似文献
3.
目的:评价奥硝唑三联疗法治疗幽门螺杆菌(Hp)相关的消化性溃疡病的疗效及其安全性。方法:将Hp检测阳性。内镜检查为活动期十二指肠溃疡的患者分为治疗组:雷贝拉唑,克拉霉素,奥硝唑;对照组:雷贝拉唑,克拉霉素,替硝唑;连用1周。然后两组继续使用雷贝拉唑1周。第28天复查内镜并检测Hp。结果:疗程结束后第28天内镜检查结果和Hp检测结果两组对比无统计学差异。结论:雷贝拉唑、克拉霉素、奥硝唑三联疗法对Hp相关的消化性溃疡病具有良好的治疗作用和安全性。 相似文献
4.
《抗感染药学》2019,(3):501-503
目的:探究泮托拉唑三联疗法(泮托拉唑、阿莫西林、克拉霉素)对胃溃疡患者伴幽门螺杆菌(Hp)感染的有效性与安全性及其对Hp清除的影响。方法:选取2017年3月—2018年6月间消化科诊治的Hp感染的胃溃疡患者82例资料,按治疗方法的不同将其随机分为对照组和治疗组,每组42例;对照组患者给予阿莫西林、克拉霉素及法莫替丁三联疗法治疗,治疗组患者则给予阿莫西林、克拉霉素及泮托拉唑三联疗法治疗;比较两组患者治疗后的总有效率、幽门螺杆菌根除率、不良反应发生率,以及治疗后溃疡复发率的差异。结果:治疗组患者治疗后的总有效率显著优于对照组(92.86%vs 64.29%()P<00.05),Hp清除率显著高于对照组(92.86%vs 73.81%()P<00.05),而不良反应发生率以及胃溃疡复发率均显著低于对照组(P<00.05)。结论:采用泮托拉唑三联疗法治疗胃溃疡患者伴有Hp感染的疗效显著优于法莫替丁三联疗法,有效清除了Hp,且安全性高和复发率低。 相似文献
5.
目的比较分析泮托拉唑与奥美拉唑为基础的三联疗法在治疗十二指肠溃疡的疗效。方法回顾分析确诊为十二指肠溃疡患者116例,随机分为泮托拉唑组和奥美拉唑组,每组各58例,两组均给予阿莫西林和克拉霉素,泮托拉唑组加服泮托拉唑,奥美拉唑组加服奥美拉唑,治疗满4周后,通过胃镜比较两组溃疡愈合的情况。结果泮托拉唑组和奥美拉唑组溃疡愈合率分别为93.1%和91.4%。两组疗效差异无统计学意义(P>0.05)。结论泮托拉唑和奥美拉唑治疗十二指肠溃疡,溃疡愈合率相当。泮托拉唑的不良反应较少。 相似文献
6.
目的评价奥硝唑三联疗法治疗幽门螺杆菌(Hp)相关的消化性溃疡的疗效及其安全性。方法将Hp检.硎阳性,内镜检查为活动期十二指溃疡的患者分为治疗组:雷贝拉唑,克拉霉素,奥硝唑;对照组:雷贝拉唑.克拉霉素,替硝唑;连用I周。然后两组继续使用雷贝拉唑1周。第二十八天复查内镜并检测Hp。结果疗程结束后第二十八天内镜检查结果和Hp检测结果两组对比无统计学差异。结论雷贝拉唑。克拉霉素,奥硝唑三联疗法对Hp相关的消化性溃疡病具有良好的治疗作用和安全性。 相似文献
7.
目的:观察泮托拉唑三联疗法治疗消化性溃疡及根除幽门螺杆菌(Hp)感染的疗效。方法:64例Hp阳性病人随机分成A、B两组各32例。A组[十二指肠溃疡(DU)14例;胃溃疡(GU)18例]给予泮托拉唑40mg,qd,po,克拉霉素500mg及阿莫西林1000mg,po,bid,疗程7d,疗程结束后继续服用泮托拉唑40mg,qd,po3wk。B组[十二指肠溃疡(DU)12例;胃溃疡(GU)20例]给予胶体次枸橼酸铋240mg及甲硝唑400mg,po,bid,四环素500mg,po,qd,疗程4wk;用药4wk后复查胃镜。结果:疗程结束后复查胃镜,A,B两组溃疡愈合率分别为91%和85%,(P>0.05)。Hp清除率分别为86%和84%,(P>0.05)。结论:泮托拉唑三联疗法治疗消化性溃疡疗效确切,无严重不良反应。 相似文献
8.
目的:就雷贝拉唑与泮托拉唑应用于治疗十二指肠溃疡的临床疗效开展比较研究.方法:随机选择2015年4月~2016年4月我院救治的100例十二指肠溃疡患者,依据用药治疗方式划分成两个组别,对照组50例接受泮托拉唑治疗,研究组50例接受雷贝拉唑治疗,就两组临床效果进行观察比较.结果:研究组总有效率100.0%相比对照组96.0%明显更优,两组之间无明显差异(P>0.05);研究组d1腹痛消失率72.0%,d2腹痛消失率90.0%,d1反酸消失率76.0%,d2腹痛消失率88.0%;对照组分别为22.0%、44.0%、20.0%,44.0%,两组之间差异明显(P<0.05).结论:雷贝拉唑应用于治疗十二指肠溃疡疗效满意,可有效改善体征症状,具备临床推广价值. 相似文献
9.
目的 通过与奥美拉唑(omeprazole)三联疗法比较,观察泮托拉唑(pantoprazole)三联疗法治疗十二指肠溃疡的疗效.方法 120例十二指肠溃疡患者分为两组:泮托拉唑组(PFC组,60例),奥美拉唑组(OFC组60例),两组均给予三联治疗:泮托拉唑40mg,奥美拉唑20mg加呋喃唑酮(furazolidone,F)100mg加克拉霉素(clarth-romycin,C)250mg,bid疗程均为4周.从服药开始经过2个月,胃镜复检,并进行幽门螺杆菌(HP)检测,并嘱患者记录药物不良反应.结果 120例十二指肠溃疡患者完成全部治疗方案,7例失访.PFC组的治愈率为94.7%,OFC组的治愈率为90.6%.结论 两组治疗方案均能有效地根除HP,治疗十二指肠溃疡.且泮托拉唑的疗效更优于奥美拉唑,且不良反应发生率远低于奥美拉唑. 相似文献
10.
雷贝拉唑三联疗法根除幽门螺杆菌感染 总被引:8,自引:1,他引:8
目的 观察雷贝拉唑三联短程疗法根除幽门螺杆菌及治疗十二指肠溃疡的疗效。方法 12 0例经胃镜检查确诊为十二指肠溃疡并经快速尿素酶实验和病理学检查确定为Hp阳性的病人随机分为两组 :雷贝拉唑组和奥美拉唑组。两组先予以三联疗法 :雷贝拉唑 10mg或奥美拉唑 2 0mg、阿莫西林 1g及克拉霉素 5 0 0mg ,每日 2次 ,连续 7d ,然后予雷贝拉唑 10mg或奥美拉唑 2 0mg ,每天 1次 ,连续 7d ,疗程结束后 4周复查胃镜并检测Hp ,并记录用药后病人症状的改变程度。结果 113例完成治疗方案。其中雷贝拉唑组Hp根除率为 93 0 % ,奥美拉唑组为 85 7% ,两组间差异无显著意义 (P >0 0 5 ) ;雷贝拉唑组 2周溃疡愈合率为 94 7% ,奥美拉唑组为 78 6 % ,雷贝拉唑组明显高于奥美拉唑组 ,两组差异有显著意义 (P <0 0 5 ) ;雷贝拉唑组第 1、3d症状缓解率分别为 70 1%、91 2 % ,奥美拉唑组为 39 3%、6 7 8% ,两组比较差异有显著意义 (P<0 0 5 )。结论 雷贝拉唑、克拉霉素和阿莫西林三联短程疗法能有效根除Hp及高溃疡愈合率 ,并能迅速缓解症状 ,与奥美拉唑三联疗法相比较 ,在Hp根除率上差异无显著意义 ,在 2周溃疡愈合率及症状缓解率方面 ,雷贝拉唑要明显优于奥美拉唑。 相似文献
11.
目的:评价奥硝唑三联疗法治疗幽门螺杆菌(HP)相关的消化性溃疡的疗效及其安全性.方法:将HP检测阳性,内镜检查为活动期十二指溃疡的患者分为治疗组,予雷贝拉唑、克拉霉素和奥硝唑;对照组予雷贝拉唑、克拉霉素和替硝唑;连用1周.然后两组继续使用雷贝拉唑1周.第28 d复查内镜并检测HP.结果:疗程结束后第28 d内镜检查结果和HP检测结果两组对比无统计学差异.结论:雷贝拉唑,克拉霉素,奥硝唑三联疗法对HP相关的消化性溃疡病具有良好的治疗作用和安全性. 相似文献
12.
目的研究质子泵抑制剂三联疗法治疗十二指肠球部溃疡的效果。方法选择80例经胃镜检查确诊Hp阳性的十二指肠球部溃疡患者,随机分为A组40例、B组40例,A组用兰索拉唑30mg,qd×4周,克拉霉素0.5g,bid×1周,阿莫西林1.0g,bid×1周;B组用法莫替丁20mg,bid×4周,克拉霉素0.5g,bid×1周,阿莫西林1.0g,bid×1周。疗程(4周)结束后,复查胃镜并做^14C呼气试验及快速尿素酶试验,比较两组的溃疡愈合率、Hp根除率。结果A、B组的溃疡愈合率分别为95.0%、82.5%,Hp根除率为92.5%、70.0%。A、B两组的溃疡愈合率、Hp根除率比较,差异有统计学意义(P〈0.05)。结论兰索拉唑二三联疗法能有效根除Hp,是治疗十二指肠球部溃疡比较理想的方法。 相似文献
13.
康复新液联合泮托拉唑三联疗法治疗幽门螺杆菌相关性消化性溃疡的临床疗效 总被引:1,自引:0,他引:1
目的观察康复新液联合泮托拉唑、阿莫西林、呋喃唑酮三联疗法治疗幽门螺杆菌(HP)相关的消化性溃疡(Pu)的疗效.方法将经胃镜检查确诊的158例幽门螺杆菌(HP)感染相关的消化性溃疡(Pu),随机分两组.对照组:78例,泮立苏40mg+阿莫西林1000mg+呋喃唑酮100mg,2次/d,三联治疗7d后,继续单用泮立苏40mg,1次/d,连服3周;治疗组80例,是在对照组基础上加服康复新液10mL,3次/d,共4周.于治疗前后进行临床症状严重程度评分,胃镜下溃疡疗效情况,HP清除情况及治疗后1年溃疡复发情况评估.结果两组治疗对比显示,治疗后都能明显缓解临床症状,而治疗组比对照组临床症状改善更为迅速,1个月后胃镜复查,溃疡愈合率,总有效率,HP清除率,治疗组分别为87.50%、97.5%、93.75%,对照组分别为51.00%、93.00%、89.74%,治疗组痊愈率优于对照组(P<0.01),总有效率及HP根除率无明显差异(P>0.05).治疗后1年溃疡复发率,治疗组20.00%,对照组42.30%,两组有显著差异(P<0.01).结论康复新液能迅速改善消化性溃疡的临床症状,促进溃疡愈合,缩短愈合疗程,减少和预防溃疡复发,康复新液联合泮立苏三联疗法治疗HP相关的消化性溃疡疗效可靠,值得推广应用. 相似文献
14.
Wong BC Chang FY Abid S Abbas Z Lin BR Van Rensburg C Chen PC Schneider H Simjee AE Hamid SS Seebaran A Zhang J Destefano M Lam SK 《Alimentary pharmacology & therapeutics》2000,14(11):1529-1535
BACKGROUND: Studies assessing the efficacy of triple therapy containing clarithromycin and amoxicillin for the eradication of Helicobacter pylori infection and healing of duodenal ulcers in Asian and African countries are limited. AIM: To determine the efficacy and safety of 1-week triple therapy with omeprazole, amoxicillin and clarithromycin for eradicating H. pylori infection in patients with active duodenal ulcer living in Asian and African regions. METHODS: This was an open-label, multicentre study in 11 centres in Asia and Africa. Patients with endoscopy-proven duodenal ulcer and who were H. pylori-positive were treated with clarithromycin 500 mg, omeprazole 20 mg, and amoxicillin 1000 mg, all given twice daily for 7 days. Upper endoscopy was repeated at week 6 to check for ulcer healing and H. pylori status. RESULTS: A total of 117 patients were recruited. H. pylori eradication rates were 85% by per protocol analysis and 80% by intention-to-treat analysis. Ulcer healing was found in 94% of subjects (per protocol analysis). Clinical success, measured by change of pre-treatment ulcer symptoms, was strongly supported by complete resolution or improvement in 100% of the evaluable patients (per protocol analysis). Since treatment-related adverse events, when present, were largely mild or moderate, the triple therapy regimen was considered safe. CONCLUSION: Seven-day triple therapy with omeprazole, amoxicillin, and clarithromycin was efficacious for treating Asian and African patients with duodenal ulcer disease associated with H. pylori infection, and the treatment regimen was well-tolerated. 相似文献
15.
泮托拉唑三联疗法治疗消化性溃疡的疗效观察 总被引:1,自引:0,他引:1
目的 探讨泮托拉唑、克拉霉素及铝碳酸镁三联疗法治疗消化性溃疡的临床疗效及不良反应.方法 选择2009年1月-2010年12月126例十二指肠球部溃疡合并幽门螺杆菌(HP)感染患者,并随机分为观察组和对照组各63例,观察组给予泮托拉唑、克拉霉素及铝碳酸镁三联疗法治疗7 d后,继续单服用泮托拉唑3周.对照组给予奥美拉唑、克... 相似文献
16.
J. LABENZ B. TILLENBURG J. WEISMÜLLER A. LÜTKE & M. STOLTE 《Alimentary pharmacology & therapeutics》1997,11(1):95-100
Background : Previous studies have shown that one-week triple therapy consisting of omeprazole, clarithromycin and amoxycillin may cure Helicobacter pylori infection in the vast majority of patients. The present study was designed to test the hypothesis that a triple therapy with pantoprazole, clarithromycin and amoxycillin cures the infection in 80% of duodenal ulcer patients infected with H. pylori .
Methods : In an open two-centre study, 60 duodenal ulcer patients were treated with pantoprazole 40 mg b.d., clarithromycin 500 mg b.d. and amoxycillin 1 g b.d. for 1 week. During the second week patients received pantoprazole 40 mg once in the morning. We assessed H. pylori infection before treatment and 4 weeks after cessation of the study medication by a rapid urease test, histology after Warthin–Starry stain and a13 C-urea breath test.
Results : Sixty patients (42 males, mean age 47.4 years) entered the trial. All patients were infected with H. pylori . One patient was withdrawn from the study because of allergy to penicillin and six patients were protocol violators. H. pylori infection was cured in 47 out of 53 patients who completed the trial according to the protocol (89%; 95% CI: 80–97%) and in 49 of 60 patients included in the trial (82%; 95% CI: 72–92%). Four weeks after the last administration of study drugs, 55 out of 60 ulcers had healed (92%). Twenty-nine patients reported 51 adverse events that were mostly mild to moderate.
Conclusions : One-week triple therapy consisting of pantoprazole, clarithromycin and amoxycillin is a simple and effective approach to the cure of H. pylori infection in patients with duodenal ulcer. In those patients who took the drugs as prescribed the H. pylori cure rate was 89%, with the lower 95% confidence limit being 80%. 相似文献
Methods : In an open two-centre study, 60 duodenal ulcer patients were treated with pantoprazole 40 mg b.d., clarithromycin 500 mg b.d. and amoxycillin 1 g b.d. for 1 week. During the second week patients received pantoprazole 40 mg once in the morning. We assessed H. pylori infection before treatment and 4 weeks after cessation of the study medication by a rapid urease test, histology after Warthin–Starry stain and a
Results : Sixty patients (42 males, mean age 47.4 years) entered the trial. All patients were infected with H. pylori . One patient was withdrawn from the study because of allergy to penicillin and six patients were protocol violators. H. pylori infection was cured in 47 out of 53 patients who completed the trial according to the protocol (89%; 95% CI: 80–97%) and in 49 of 60 patients included in the trial (82%; 95% CI: 72–92%). Four weeks after the last administration of study drugs, 55 out of 60 ulcers had healed (92%). Twenty-nine patients reported 51 adverse events that were mostly mild to moderate.
Conclusions : One-week triple therapy consisting of pantoprazole, clarithromycin and amoxycillin is a simple and effective approach to the cure of H. pylori infection in patients with duodenal ulcer. In those patients who took the drugs as prescribed the H. pylori cure rate was 89%, with the lower 95% confidence limit being 80%. 相似文献
17.
目的 观察埃索美拉唑一周三联疗法治疗十二指肠溃疡的近期与远期疗效.方法 将经内镜证实的十二指肠溃疡Hp阳性患者随机分为EAC组45例和OAC组35例,EAC组2次/d口服埃索美拉唑20 mg、阿莫西林1000 mg、克拉霉素500 mg,疗程1周;OAC组用药除用奥美拉唑20 mg代替埃索美拉唑外,其余与EAC组相同,用药1周后停用抗生素,继续单用奥美拉唑20 mg,2次/d,治疗3周停药.用药期间观察症状缓解情况和不良反应,疗程结束后复查内镜观察溃疡愈合情况,检测Hp,对两组愈合患者追踪随访1年,观察溃疡复发情况.结果 EAC组症状缓解率、溃疡愈合率、Hp根除率、溃疡复发率分别为100%、93%、86.7%、7.1%,OAC组分别为100%、97%、88.6%、59%,两组对比差异无统计学意义(P>0.05),两组均无严重不良反应.结论 埃索美拉唑一周三联疗法治疗十二指肠溃疡具有很高的Hp根除率和溃疡愈合率,缓解症状迅速,复发率低,患者依从性及安全性好,费用亦较传统治疗方案降低. 相似文献